Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro

By Desta Zeruesenay   Saussele Tanja   Ward Bryan   Blievernicht Julia   Li Lang   Klein Kathrin   Flockhart David A   Zanger Ulrich M  

Pharmacogenomics, Vol. 8, Iss. 6, 2007-06 ,pp. : 547-558

Future Medicine

Access to resources Recommend Favorite

Would a CYP2B6 test help HIV patients being treated with efavirenz?

By Sukasem Chonlaphat   Sungkanuparph Somnuek  

Pharmacogenomics, Vol. 14, Iss. 9, 2013-07 ,pp. : 999-1001

Future Medicine

Access to resources Recommend Favorite

CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 Polymorphisms in Two Bantu-Speaking Populations from Cameroon and South Africa: Implications for Global Pharmacogenetics

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 10, Iss. 1, 2012-03 ,pp. : 43-53

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular Characterization of CYP2B6 Substrates

By  

Current Drug Metabolism, Vol. 9, Iss. 5, 2008-06 ,pp. : 363-373

Bentham Science Publishers

Access to resources Recommend Favorite

Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment

By Walko Christine M   McLeod Howard  

Pharmacogenomics, Vol. 13, Iss. 6, 2012-04 ,pp. : 691-697

Future Medicine

Access to resources Recommend Favorite